Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seltorexant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 known ✓ | O43614 | 20/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seltorexant SCHEMBL1671257 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Seltorexant SCHEMBL19341242 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Seltorexant SCHEMBL29711733 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Seltorexant SCHEMBL22018191 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Seltorexant SCHEMBL17270584 | 0.99 | HCRTR1 (0.98) | HCRTR1HCRTR2KCNH2 | |
| Seltorexant SCHEMBL29577602 | 0.99 | HCRTR1 (0.98) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL1670950 | 0.95 | HCRTR1 (0.91) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL6924177 | 0.93 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL1671595 | 0.92 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL1672658 | 0.92 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734999-A1 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | claimed |
| WO-2025242852-A1 | SELTOREXANT FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | WO | claimed |
| US-20250221992-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-10 | — | — | US | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250154158-A1 | SOLID STATE FORMS OF SELTOREXANT | TEVA CZECH INDUSTRIES S.R.O. | 2025-05-15 | — | — | US | claimed |
| US-20250082635-A1 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-13 | — | — | US | claimed |
| US-12201634-B2 | Methods of treating depression using orexin-2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-21 | — | — | US | claimed |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | claimed |
| WO-2023164385-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023163879-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023163964-A1 | SOLID STATE FORMS OF SELTOREXANT | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164386-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164387-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| CN-108883110-B | Methods of treating depression using orexin-2 receptor antagonists | 詹森药业有限公司 | 2022-05-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154158-A1 | SOLID STATE FORMS OF SELTOREXANT | SELE, SELP, SELPLG | HCRTR2 3388/4885HCRTR1 3010/4885KCNH2 4261/4885 |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | HCRTR2 38/4885HCRTR1 64/4885KCNH2 4501/4885 |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | HCRTR2 38/4885HCRTR1 64/4885KCNH2 4501/4885 |
| US-20250221992-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 666/4885 |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | HCRTR2 38/4885HCRTR1 64/4885KCNH2 4501/4885 |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | HCRTR2 38/4885HCRTR1 64/4885KCNH2 4501/4885 |
| US-12201634-B2 | Methods of treating depression using orexin-2 receptor antagonists | HCRTR2, HCRTR1, CRHR2 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 666/4885 |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR2, HCRTR1, HTR2A | HCRTR2 1/4885HCRTR1 2/4885KCNH2 2126/4885 |
| US-20250082635-A1 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | HCRTR2, HCRTR1, CRHR2 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.